IDH1 and cholangiocarcinoma: Additionally, it has to be taken into account that the treatment landscape of CCA has changed with the introduction of PD‐(L)1 inhibitors in combination with cisplatin and gemcitabine [4, 5] and that most data about the prognostic and predictive impact of IDH1 mutations on second and further line treatments do not include patients treated with the new first‐line standard of care.